Non-human primate model(Cynomolgus) with spontaneously developed diabetes mirror every aspects of the human disease, including:
• Obesity
• Hyperglycemia
• Hyperinsulinemia
• Dyslipidemia
• Glucose intolerance (oGTT & ivGTT)
• Reduced glucose disposition (hyperglycemia clamp)
• Insulin resistance (Euglycemic & hyperinsulinemic clamp)
• Insulin dependency at late stage
Similar to humans, monkeys also develop high-fat-diet-induced dyslipidemia.
Therefore, our in vivo pharmacology method in NHP provide the highest level of confidence for the go/no go decision making in the drug discovery process. These studies not only provide deep biological insights into the pharmacological mechanisms of a drug, but also identify biomarkers important to clinical trial design (i.e. patient stratification and study rational).